Cycle on May 25, 2026

I will list the open threads for this topic to understand what specific areas require follow-up or investigation in this research cycle.

I will search for recent news on the Medicare GLP-1 Bridge program and other GLP-1 developments to identify what has happened in the last few days (since May 24, 2026) and see if there are updates on the Medicare GLP-1 Bridge program.

The MSN/Motley Fool article from May 21-23, 2026 says "Medicare beneficiaries hoping for GLP-1 coverage for weight loss just got some bad news" and "The GLP-1 Bridge... has been indefinitely postponed". This is a massive, highly critical news update! If the Medicare GLP-1 Bridge program has been indefinitely postponed or canceled recently, this completely shifts the landscape. Let me fetch these articles to verify. I will fetch the JDSupra article, the Motley Fool article (or MSN), and search for more details on this postponement. Let's do a fast search for "Medicare GLP-1 Bridge postponed" or "Medicare GLP-1 Bridge cancelled" to get the exact details.

Let's fetch the Motley Fool article directly using web_fetch. URL: `https://www.fool.com/retirement/2026/05/21/medicare-beneficiaries-hoping-for-glp-1-coverage-f/` Wait, let's look at the MSN link first, or the Motley Fool URL. I will fetch both or one of them. Let's do a fetch for the Motley Fool page.

Ah, this is fascinating! Let's analyze the details here carefully: - The **BALANCE model** (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) was originally scheduled to take effect in January 2027. This would have allowed Medicare Part D sponsors to decide whether to cover GLP-1s for weight loss. This BALANCE model has been **tabled indefinitely** (delayed with no indication of when it will take effect). - However, the **Medicare GLP-1 Bridge program** is **NOT** postponed. In fact, it's starting on **July 1, 2026** and has been **extended through December 31, 2027** (it was initially only supposed to last through the end of 2026). - The "bad news" in the Motley Fool article is that the *BALANCE model* (the permanent program) has been indefinitely postponed, and because the *Bridge program* operates outside of Medicare Part D plans, any money spent on GLP-1s won't count toward the Medicare Part D deductible or out-of-pocket maximum. Let's do some more research on this. I want to search for "BALANCE model" "Medicare" "GLP-1" "postponed" or "delayed" to see exactly what CMS announced and why, and what the extension of the Bridge program entails. Let's do a search.

Let's look at the search results. Ah, look at this result from Becker's Hospital Review: `Trump bought Eli Lilly stock as his administration cleared path for Medicare GLP-1 coverage` "And by late April, CMS announced that the BALANCE Model's Medicare Part D ... CMS instead extended the Medicare GLP-1 Bridge through December 2027. Eli ..." This sounds fascinating and contains concrete policy and corporate details. Let's do a search on this specific story to see what Becker's or other news outlets wrote about it. This would be highly relevant for an investor. Let's search for: `Trump bought Eli Lilly stock as his administration cleared path for medicare GLP-1 coverage`.

Let's fetch the Becker's Hospital Review page about Trump buying Eli Lilly stock as the administration cleared the path for Medicare GLP-1 coverage. This seems like a major development in the political, regulatory, and financial landscape of GLP-1s. Let's fetch it.

Wow, this is an incredible, highly detailed, and extremely informative article! Let's unpack the key pieces of information from this article: 1. **President Trump's Stock Purchases of Eli Lilly (Q1 2026)**: - Federal ethics disclosures (OGE Form 278-T) published recently (made public May 14, 2026) show Donald Trump's accounts purchased Eli Lilly stock on at least seven occasions in Q1 2026 (Jan–March 2026). - This occurred as his administration took major actions benefiting Eli Lilly's obesity drug business. - The first purchase was Jan 6, 2026, two days before the Jan 8 deadline for drug manufacturers to submit applications to participate in CMS's BALANCE Model (announced Dec 23, 2025). - The disclosures cover January through March 2026. The cumulative value of all trades across thousands of securities was between $220 million and $750 million. 2. **CMS BALANCE Model and Medicare GLP-1 Bridge Program Updates**: - CMS's **BALANCE Model** (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) was proposed to negotiate GLP-1 drug prices directly with manufacturers on behalf of state Medicaid agencies and Medicare Part D plans. - **The Medicare GLP-1 Bridge** is a separate, faster-moving component launching **July 1, 2026**, giving eligible Part D beneficiaries access to obesity drugs for a **$50 monthly copay**. - **BALANCE Model Delay**: In late April 2026, CMS announced that the BALANCE Model's Medicare Part D component would **not launch as scheduled in January 2027**, citing **insufficient plan participation**. This setback sent Lilly and Novo Nordisk shares lower. - **Bridge Extension**: To compensate, CMS **extended the Medicare GLP-1 Bridge through December 31, 2027** (it was initially only through the end of 2026). - Eli Lilly confirmed in its filings that Zepbound, Mounjaro, and Foundayo are participating. 3. **Eli Lilly's Oral GLP-1 "Foundayo" (Orforglipron) Approved**: - In **April 2026**, the FDA approved Eli Lilly's oral GLP-1 weight loss drug **Foundayo** (orforglipron) under a new expedited review program. - It was cleared in **50 days** — the fastest approval for a novel drug since 2002 — using the Commissioner's National Priority Voucher program launched by then-FDA Commissioner Marty Makary, MD (who stepped down May 12, 2026). - Foundayo is immediately available via LillyDirect, with retail pharmacy availability to follow. - Safety concern: The FDA requested additional safety data on liver toxicity associated with Foundayo. 4. **Compounded GLP-1 Crackdown**: - The FDA declared the tirzepatide shortage resolved in Dec 2024 and semaglutide shortage resolved in Feb 2025. - By early 2026, the FDA had sent 30 warning letters to telehealth companies marketing compounded semaglutide and tirzepatide. - In **April 2026, the FDA proposed formally excluding all three major GLP-1 compounds from the 503B bulk substances list**, which would close the last regulatory pathway for large-scale compounding regardless of future shortage conditions. (This is a massive hit to compounding pharmacies and telehealth companies that rely on them!) Let's check if there are other recent updates or developments in the GLP-1 space, such as Novo Nordisk earnings, competitors, or other clinical trials. Wait, let's search for "Novo Nordisk" or "Eli Lilly" pipeline updates, or competitor trials in May 2026 to see if there are other major milestones. Specifically, let's look for "CagriSema" or "survodutide" or other competitors. Let's do a search for: `Novo Nordisk CagriSema clinical trial results 2026` or `Eli Lilly pipeline 2026` or `"survodutide" 2026`.

Oh my goodness, this is a massive milestone! Let's fetch the Eli Lilly press release and/or the BioPharma Dive article to get the exact numbers, quotes, and statistics from the Phase 3 TRIUMPH-1 trial of **retatrutide** that was announced on **May 21, 2026**! First, let's fetch the investor release from Eli Lilly: URL: `https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss` And let's also fetch the BioPharma Dive article or Clinical Trials Arena article to understand the analyst concerns regarding tolerability / adverse events (AEs). Let's fetch the Eli Lilly investor release first.

Ah, the firecrawl fetch timed out. Let's try fetching the AJMC article or the BioPharma Dive article, or the CNBC article, or try the Eli Lilly investor release again if we think it was a transient network issue. Let's first try fetching the AJMC article: `https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial` If that fails, let's try the CNBC or BioPharma Dive URLs. Let's do a fetch for AJMC.

This is spectacular data! Let's summarize the key details of the **retatrutide** Phase 3 **TRIUMPH-1** trial: - **Drug**: Retatrutide, a first-in-class triple hormone receptor agonist (GIP, GLP-1, and glucagon). - **Trial**: Phase 3 TRIUMPH-1 trial (NCT05929066), 2,339 participants with obesity or overweight and at least 1 weight-related comorbidity, without diabetes. - **Results at 80 weeks**: - High-dose (12 mg) group: **28.3% average weight loss** (70.3 lbs) from baseline average of 248.5 lbs. - **45.3%** of participants on the 12 mg dose achieved **≥30% body weight reduction** (surgical level!). - **65.3%** of participants on the 12 mg dose reduced their weight below the obesity threshold (BMI < 30 kg/m²). - 9 mg group: **25.9% average weight loss** (64.4 lbs). - 4 mg group: **19.0% average weight loss** (47.2 lbs). - **Results at 104 weeks (blinded extension for BMI ≥35 kg/m²)**: - 12 mg group: **30.3% average weight loss** (85.0 lbs) from an average baseline of 268.3 lbs. This is a historic milestone (breaking the 30% barrier!). - **Adverse Events & Discontinuations**: - Gastrointestinal side effects were common, with nausea in 42.4% of the 12 mg group (vs 14.8% placebo) and vomiting in 25.3% of the 12 mg group (vs 4.8% placebo). - Discontinuations due to adverse events increased with dose: **4.1%** for 4 mg, **6.9%** for 9 mg, and **11.3%** for 12 mg (vs 4.9% placebo). This shows that while efficacy is unprecedented, tolerability at high doses (12 mg) is a concern (with 1 in 9 patients discontinuing). Let's do some more search. I should check other competitor pipeline news or market reactions. Wait, let's search for "Novo Nordisk" "CagriSema" or other competitor weight loss drugs in May 2026. Let's do a search on: `Novo Nordisk CagriSema clinical trial results 2026` or `"CagriSema" phase 3 2026`.

Ah, this is very interesting! Let's examine the Novo Nordisk pipeline news: - There is a lot of focus on **Novo Nordisk's MASH (metabolic dysfunction-associated steatohepatitis) data** at the EASL (European Association for the Study of the Liver) conference, which just happened or is happening in May 2026. - The **CagriSema** FDA decision is due in **December 2026** (or late 2026), but there were some mixed trial results earlier this year. The trial revealed CagriSema achieved only 20% weight loss over 84 weeks in some trials, and "CagriSema missed non-inferiority vs Lilly". - Let's search for "Novo Nordisk" "MASH" "EASL" 2026 or "semaglutide" "MASH" "EASL" 2026 to see what the clinical data was. This would be a major expansion of GLP-1 applications (MASH/NASH is a massive market!). Let's do a search.

Let's fetch the GlobeNewswire press release from Novo Nordisk (May 19, 2026) or the BioPharm International page to see the exact results and quotes. Let's use GlobeNewswire first: `https://www.globenewswire.com/news-release/2026/05/19/3297439/0/en/novo-nordisk-to-unveil-data-showing-semaglutide-tackles-the-liver-disease-crisis-affecting-about-1-in-3-people-living-with-overweight-and-obesity-worldwide.html` Let's do a fetch.

The firecrawl scrape timed out again. Let's try fetching the BioPharm International page or the Indian Pharma Post page, or find a different URL. Let's try fetching `https://www.biopharminternational.com/view/novo-nordisk-highlights-semaglutide-liver-safety-and-subgroup-data-in-mash-at-easl-2026`. If that fails, let's try a search to pull more text or find a simpler site. Let's fetch BioPharm International.

Excellent! This gives us a solid overview of Novo Nordisk's MASH clinical efforts. Let's note that this is based on their Phase 3 ESSENCE trial program evaluating semaglutide 2.4 mg in patients with MASH and liver fibrosis, with data presented at EASL Congress 2026 (May 2026). Let's do a search on other major GLP-1 developments, such as the impact on medical device companies (e.g., continuous glucose monitors - Dexcom, Abbott, or bariatric surgery companies like Intuitive Surgical) or consumer adoption trends. Let's search for: `Dexcom Abbott GLP-1 earnings 2026` or `Dexcom Abbott "GLP-1" 2026` or `bariatric surgery "GLP-1" 2026`.

Wow, this is an incredible set of search results! We have multiple highly recent (May 2026) articles and studies that show a dramatic drop in bariatric surgeries and a massive rise in GLP-1 prescriptions. Let's look at the specific numbers from the Harvard Chan School study: - Metabolic bariatric surgery (MBS) utilization decreased by **34.1%** from 2022 to 2025. - Prescriptions for GLP-1 receptor agonists increased by **140.4%** in the same period. - Let's search for "Harvard Chan School" bariatric surgery GLP-1 2026 or fetch the physiciansweekly or medicalxpress page. Let's try fetching the Physicians Weekly or Harvard Chan School article. Let's check the Harvard T.H. Chan School of Public Health page or Physicians Weekly page. Let's fetch `https://www.physiciansweekly.com/post/metabolic-bariatric-surgery-use-plunges-amidst-glp-1-prescribing-surge` or `https://hsph.harvard.edu/news/bariatric-surgeries-on-the-decline-as-use-of-glp-1-drugs-rises/` (let's do both or one of them). Let's fetch physiciansweekly first.

This is highly citable and incredibly specific! Let's summarize this finding: - **Study published in**: *JAMA Surgery* on May 13, 2026 (online). - **Authors**: Thomas C. Tsai, MD, MPH (American College of Surgeons, Harvard T.H. Chan School of Public Health, Brigham and Women's Hospital) and colleagues. - **Data source**: IQVIA PharMetrics Plus with Mortality data, tracking 11.7 million adults with at least one diagnosis of overweight, obesity, or diabetes and continuous coverage from 2022 to 2025 (specifically 2022 through 2024). - **Key finding 1**: Metabolic bariatric surgery (MBS) utilization **decreased by 34.1%** overall during the study period (2022–2024). - Between 2022 and 2023, MBS patients declined 14.4% (from 2.0 to 1.7 patients per 1,000). - This trend accelerated in 2024 with a year-on-year relative **23.0% decrease** in patients undergoing MBS. - **Key finding 2**: Prescriptions for GLP-1 receptor agonists **increased by 140.4%** over the same period. - Between 2022 and 2023, there was a 71.8% relative increase in patients filling GLP-1s (from 36.2 to 62.1 patients per 1,000). - Growth continued between 2023 and 2024 with a 39.9% relative increase. - **Key finding 3**: Obesity remains highly undertreated overall. Only about **9.5%** of the eligible population (diagnosed with overweight, obesity, or diabetes) underwent treatment with either GLP-1s or MBS, despite the spike. This is a massive point for medical device investors (like Intuitive Surgical, Ethicon/Johnson & Johnson, Medtronic, which manufacture instruments and robots for bariatric surgeries). This 34% drop in bariatric surgery rates represents a dramatic shift in the commercial market for medical devices. Let's do a search on other medical device areas like Continuous Glucose Monitors (CGMs). Wait, what is happening with Dexcom and Abbott? Let's search for `Dexcom Abbott GLP-1 2026` or `Dexcom Abbott CGM market share 2026`.

Ah, look at this: - **Dexcom G8**: Dexcom has unveiled details of its next-generation continuous glucose monitor, the **Dexcom G8** (May 2026). - **Dexcom Flex**: On May 19, 2026, Dexcom announced the launch of **Dexcom Flex**, a new continuous glucose monitor (CGM) for adults with type 2 diabetes who are not on insulin but are on other therapies like GLP-1 receptor agonists. It was launched in Germany first. Let's search for "Dexcom Flex" to see what it is and why it's targeted at GLP-1 users. Let's do a search on: `"Dexcom Flex" CGM 2026`.

Let's fetch the BusinessWire press release for Dexcom Flex to see the exact details and quotes: URL: `https://www.businesswire.com/news/home/20260518266091/en/Redefining-CGM-for-People-With-Type-2-Diabetes-Dexcom-Announces-Dexcom-Flex-in-Germany` Let's fetch it.

This is a highly relevant finding for medical device investors in the continuous glucose monitoring (CGM) sector! - **Product**: Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy (i.e., those on basal insulin, oral medications, or GLP-1 receptor agonists). - **Strategy**: Dexcom is expanding CGM access to a broader Type 2 diabetes population earlier in their journey, specifically targeting those using GLP-1 receptor agonists. - **Rollout**: Initial launch in Germany, with plans to expand. This follows Dexcom's launch of Stelo (its over-the-counter CGM) and Abbott's Lingo/Rio OTC monitors. - **Significance for investors**: This is a direct strategic response by CGM manufacturers to the GLP-1 boom. Instead of seeing GLP-1s purely as a threat to CGM adoption (due to improved glycemic control without insulin), Dexcom is positioning CGMs as a *companion* tool for GLP-1 users to track behavioral changes, food impact, and avoid rare hypoglycemic events. This expands the addressable market (TAM) for CGMs beyond intensive-insulin users. Let's do a search on the study mentioned in the Physicians Weekly article regarding the Reddit posts and AI: `AI scans 400,000 Reddit posts and finds hidden Ozempic side effects` Let's search for this to see what consumer adoption and side-effect trends are being discussed. This could be highly relevant for consumer adoption and emerging trends. Let's search for: `AI 400,000 Reddit posts "Ozempic" 2026`.

Ah! My web search budget is exhausted. No problem. I have several incredibly rich, high-quality, and highly relevant sources that I fetched during this run, giving me plenty of concrete evidence to write extremely strong, detailed findings. Let's review the findings we can write: 1. **Eli Lilly's Next-Gen Triple Agonist Retatrutide Shatters Efficacy Benchmarks in Phase 3 TRIUMPH-1 Trial**: - Source: AJMC article (`https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial`), which covers the May 21, 2026 announcement. - Key evidence: 28.3% average weight loss at 80 weeks for the 12 mg dose, up to 30.3% average weight loss at 104 weeks in the blinded extension. Over 45% of patients achieved ≥30% weight loss. Discontinuation rates (tolerability) are dose-dependent, reaching 11.3% at 12 mg. - Interpret: This sets a new surgical-level benchmark for pharmacotherapy, positioning Lilly to dominate the next-generation landscape, though at the cost of higher GI discontinuations. 2. **The Medicare GLP-1 Coverage Split: CMS Delays Permanent BALANCE Model but Extends $50/Month Bridge Program Through 2027**: - Source: Motley Fool (`https://www.fool.com/retirement/2026/05/21/medicare-beneficiaries-hoping-for-glp-1-coverage-f/`) and Becker's Hospital Review (`https://www.beckershospitalreview.com/pharmacy/trump-bought-eli-lilly-stock-as-his-administration-cleared-path-for-medicare-glp-1-coverage.html`). - Key evidence: CMS indefinitely postponed the permanent BALANCE model (originally set for Jan 2027) due to insufficient plan participation. However, CMS extended the temporary Medicare GLP-1 Bridge program (launching July 1, 2026) through December 31, 2027 (originally set to expire at the end of 2026). Bridge-related spending does not count toward Part D out-of-pocket maximums or deductibles. - Ethics disclosures: Becker's revealed that President Trump purchased Eli Lilly stock on at least seven occasions in Q1 2026, a period in which his administration took multiple policy actions (such as the BALANCE model and Bridge program) that benefited Lilly's business. 3. **Bariatric Surgery Rates Plunge 34% as GLP-1 Prescriptions Surge 140% (JAMA Surgery Study)**: - Source: Physicians Weekly (`https://www.physiciansweekly.com/post/metabolic-bariatric-surgery-use-plunges-amidst-glp-1-prescribing-surge`) covering the *JAMA Surgery* study published online May 13, 2026 by Dr. Thomas C. Tsai and colleagues. - Key evidence: Bariatric surgery utilization plunged 34.1% from 2022 to 2024 (with a 23% year-on-year drop in 2024 alone), while GLP-1 prescriptions spiked 140.4%. - Interpret: This confirms the long-feared structural threat to bariatric medical devices (Intuitive Surgical, Johnson & Johnson, Medtronic) and highlights that pharmacotherapy is rapidly replacing surgical intervention. 4. **Dexcom Launches "Dexcom Flex" CGM in Germany as CGM Makers Pivot to Target GLP-1 Users**: - Source: BusinessWire (`https://www.businesswire.com/news/home/20260518266091/en/Redefining-CGM-for-People-With-Type-2-Diabetes-Dexcom-Announces-Dexcom-Flex-in-Germany`) announced May 18, 2026. - Key evidence: Dexcom Flex is specifically designed for Type 2 diabetes patients who are not on intensive insulin therapy, explicitly targeting those on basal insulin, oral meds, or GLP-1 receptor agonists. - Interpret: This represents a strategic pivot by CGM manufacturers to capture the massive GLP-1 user base, positioning CGMs as a companion behavioral tool rather than a tool solely for insulin titration. 5. **Novo Nordisk Unveils Phase 3 ESSENCE Subgroup Data in MASH at EASL 2026**: - Source: BioPharm International (`https://www.biopharminternational.com/view/novo-nordisk-highlights-semaglutide-liver-safety-and-subgroup-data-in-mash-at-easl-2026`) covering May 19, 2026 data. - Key evidence: Novo Nordisk presented Phase 3 ESSENCE trial subgroup analyses on semaglutide 2.4 mg (Wegovy) in patients with MASH (metabolic dysfunction-associated steatohepatitis) and liver fibrosis. The analyses demonstrated favorable hepatic safety across subgroups, including menopausal women and Japanese patient populations. - Interpret: This bolsters Novo Nordisk's medical case for expanding Wegovy's label to MASH, which affects an estimated 250 million people globally, opening up a massive secondary market. Wait, let's write a cycle summary note that integrates all these findings and updates the research landscape. Let's look at the prior findings that were auto-retrieved: - `cycle-summary-2026-05-24` (and earlier). Let's write a new cycle summary note or update the prior one. The prompt says: "When writing a finding that refines one of the above, reuse its slug to update. Otherwise pick a fresh slug." Since this is a new research cycle ending on May 25, 2026, we should write a new cycle summary note with a fresh slug (e.g., `cycle-summary-2026-05-25`), and write the individual detailed findings with fresh slugs. Wait, let's see if there are other files in our workspace. The guidelines say: "Before modifying a file, read it first. Do not assume files or directories exist." Let's check if there are any other files. No, we are just writing findings as topic notes using `write_note`. Let's write the findings. ### Finding 1: Eli Lilly's Retatrutide Shatters Efficacy Benchmarks in Phase 3 TRIUMPH-1 Trial, Reaching 30% Weight Loss Let's write this finding. We will use the slug `retatrutide-phase3-triumph1-results-30-percent`. Let's construct the markdown body with verbatim quotes and sources. Wait, let's double check the verbatim quotes from the AJMC article: - Quote 1: "According to the primary efficacy end point, participants on the highest dose of retatrutide (12 mg) achieved an average weight loss of 70.3 lb (28.3%) from a baseline average of 248.5 lb (body mass index [BMI], 40.0 kg/m²). Notably, 45.3% of individuals in the 12-mg cohort achieved a body weight reduction of 30% or greater—a threshold historically associated with bariatric surgery." - Quote 2: "By week 104, individuals initially randomized to the 12-mg arm achieved an average total weight loss of 85.0 lb, representing a 30.3% reduction from an average baseline of 268.3 lb (BMI, 42.8 kg/m²)." - Quote 3: "Discontinuation rates due to adverse events correlated directly with dosage escalation. The 4-mg arm demonstrated a 4.1% discontinuation rate—lower than the 4.9% rate observed in the placebo group. Discontinuation rates rose to 6.9% in the 9-mg group and 11.3% in the 12-mg group." Let's write this first finding.

Excellent! Now let's write the second finding: **The Medicare GLP-1 Coverage Split: CMS Delays Permanent BALANCE Model but Extends $50/Month Bridge Program Through 2027**. Wait, this finding refines a prior finding: `oral-obesity-pills-approved-medicare-glp1-bridge`. Let's see if we should reuse its slug or write a separate finding. The prior finding is titled "The Rise of Oral Obesity Pills and the Expanded Medicare GLP-1 Bridge Program". Since our new finding is a direct update on the Medicare GLP-1 Bridge program (the delay of the BALANCE model, the extension of the Bridge program through 2027, and the political/ethics disclosures around Trump's Eli Lilly stock trades during this exact policy period), we can reuse the slug `oral-obesity-pills-approved-medicare-glp1-bridge` to update it or write a new one if it's different. Wait, let's reuse the slug `oral-obesity-pills-approved-medicare-glp1-bridge` as requested by the guidelines: "When writing a finding that refines one of the above, reuse its slug to update." Let's look at the prior finding's title: "The Rise of Oral Obesity Pills and the Expanded Medicare GLP-1 Bridge Program". Let's read the details we gathered: - CMS postponed the permanent BALANCE model (Part D component) because of "insufficient plan participation". - CMS extended the temporary Medicare GLP-1 Bridge program through **December 31, 2027** (it launches July 1, 2026). - Out-of-pocket spending on the Bridge program does *not* count toward the Medicare Part D deductible or out-of-pocket maximum. - FDA approved Eli Lilly's oral GLP-1 **Foundayo** (orforglipron) in April 2026 under an expedited 50-day review. - Ethics disclosures published May 14, 2026 show President Trump's accounts bought Eli Lilly stock at least seven times in Q1 2026. - The FDA proposed formally excluding semaglutide, tirzepatide, and orforglipron from the 503B bulk substances list in April 2026, which would shut down large-scale compounding. Let's write this update to `oral-obesity-pills-approved-medicare-glp1-bridge` in a highly comprehensive note.

Excellent! Let's write the third finding: **Bariatric Surgery Rates Plunge 34% as GLP-1 Prescriptions Surge 140% (JAMA Surgery Study)**. Let's use a fresh slug: `bariatric-surgery-plunges-glp1-prescriptions-surge`. Let's look at the verbatim quotes from the Physicians Weekly article: - Quote 1: "Metabolic bariatric surgery (MBS) utilization decreased by 34% from 2022 to 2025, while prescriptions for glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) increased by 140% over the same period, according to a research letter published in JAMA Surgery." - Quote 2: "In contrast, there has been a significant decline in MBS utilization, with an overall decline of 34.1% during the study period of 2022 through 2024 (P <0.001). Between 2022 and 2023, patients undergoing MBS declined 14.4% (2.0 to 1.7 MBS patients per 1000). This trend accelerated in 2024, with a year-on-year relative 23.0% decrease in patients undergoing MBS." - Quote 3: "Despite the increase in GLP-1s, our study shows that obesity remains undertreated, with only about 9.5% of the relevant population undergoing treatment with GLP-1s or MBS." Let's write this finding.

Incredible! Now let's write the fourth finding: **Dexcom Launches "Dexcom Flex" CGM in Germany as CGM Makers Pivot to Target GLP-1 Users**. Let's use a fresh slug: `dexcom-launches-flex-cgm-germany-glp1-users`. Let's look at the verbatim quotes from the BusinessWire press release: - Quote 1: "Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists. The new system will be available shortly." - Quote 2: "Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population." - Quote 3: "By supporting people earlier in their Type 2 journey, before they require intensive insulin therapy, Flex may help improve long‑term health outcomes and contribute to meaningful reductions in diabetes-related complications." Let's write this finding.

Excellent! Now let's write the fifth finding: **Novo Nordisk Unveils Phase 3 ESSENCE Subgroup Data in MASH at EASL 2026**. Let's use a fresh slug: `novo-nordisk-mash-essence-easl-2026`. Let's look at the verbatim quotes from the BioPharm International article: - Quote 1: "Novo Nordisk presented new EASL 2026 data highlighting semaglutide’s liver safety profile and subgroup efficacy in metabolic dysfunction-associated steatohepatitis, reinforcing the growing role of GLP-1 therapies in chronic liver disease management." - Quote 2: "The data presentations expand upon findings from the company’s Phase 3 ESSENCE trial program evaluating semaglutide 2.4 mg in patients with MASH and liver fibrosis." - Quote 3: "According to Novo Nordisk, the new analyses focused on hepatic safety, menopausal women, and Japanese patient populations—groups often underrepresented in liver disease research." Let's write this finding.

Excellent! Let's write the final Research Cycle Summary note for this cycle. We will use a fresh slug: `cycle-summary-2026-05-25`. Wait, let's look at the structure of a cycle summary note. The guidelines state: "A cycle-summary note that links to other cycle notes is fine and doesn't itself need an external URL, but every substantive finding must." Let's construct a beautiful, comprehensive summary of the five findings we wrote this cycle, detailing the major updates for an investor watching the GLP-1 space. Let's do a write_note for the cycle summary.

Now let's review our open threads. We have an open thread: `019e5904-f0be-7639-93ed-604d720010ca` Title: "Track the operational rollout, pharmacy claims volume, and patient uptake of the extended Medicare GLP-1 Bridge program starting July 1, 2026" Let's look at the description: "The Medicare GLP-1 Bridge program launches on July 1, 2026, and runs through December 31, 2027. A future cycle should track the operational rollout, pharmacy claims volume, physician attestation rates, and the initial volume/expenditure impact of this program on Medicare's budget and the manufacturers' rebates." Since the launching of the program is still in the future (July 1, 2026, and today is May 25, 2026), we should keep this thread open for future cycles to track. Wait, let's see if we should open any new threads. Are there any other open questions that we should record? We could record a thread to track: 1. **The FDA final decision on CagriSema expected in December 2026**: We found that Novo Nordisk is awaiting an FDA decision on CagriSema in Dec 2026, which is a major competitive catalyst against Lilly. 2. **The FDA final rule on excluding GLP-1s from the 503B bulk substances list**: This will determine whether compounding pharmacies are permanently shut out of the GLP-1 market, which is a massive commercial catalyst for Lilly and Novo Nordisk. Let's record these as new threads or a combined thread to track key regulatory and pipeline catalysts in late 2026. Let's record a thread using `record_thread`.

Excellent! The thread is recorded. Let's double-check if we need to resolve any threads. The open thread `019e5904-f0be-7639-93ed-604d720010ca` is about tracking the rollout starting *July 1, 2026*. Since we are currently on May 25, 2026, the program has not launched yet, so we cannot resolve this thread. We will leave it open. Let's call `finish_cycle` to complete this research cycle. This is the ONLY way to end a cycle. Let's do it.

I have completed the research cycle and documented five major findings on the GLP-1 drug boom and its ripple effects across healthcare, along with a comprehensive summary. I also opened a new tracking thread for key late-2026 pipeline and regulatory catalysts. Notes and threads are listed below.